NL8303211A - Nieuwe farmaceutische preparaten op basis van cisplatinum en werkwijze voor het bereiden daarvan. - Google Patents
Nieuwe farmaceutische preparaten op basis van cisplatinum en werkwijze voor het bereiden daarvan. Download PDFInfo
- Publication number
- NL8303211A NL8303211A NL8303211A NL8303211A NL8303211A NL 8303211 A NL8303211 A NL 8303211A NL 8303211 A NL8303211 A NL 8303211A NL 8303211 A NL8303211 A NL 8303211A NL 8303211 A NL8303211 A NL 8303211A
- Authority
- NL
- Netherlands
- Prior art keywords
- cisplatinum
- sterile
- lyophilized
- product
- stable
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 3
- 239000000243 solution Substances 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 238000004108 freeze drying Methods 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 11
- 229930195725 Mannitol Natural products 0.000 claims description 11
- 239000000594 mannitol Substances 0.000 claims description 11
- 235000010355 mannitol Nutrition 0.000 claims description 11
- 239000008227 sterile water for injection Substances 0.000 claims description 10
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 239000008223 sterile water Substances 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 2
- 238000011275 oncology therapy Methods 0.000 claims 2
- 230000002349 favourable effect Effects 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- 239000008215 water for injection Substances 0.000 description 11
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 8
- 230000008014 freezing Effects 0.000 description 7
- 238000007710 freezing Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000013543 active substance Substances 0.000 description 6
- 229910052697 platinum Inorganic materials 0.000 description 6
- 150000004985 diamines Chemical class 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- -1 cis-platinum (II) diamine Chemical class 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229920005556 chlorobutyl Polymers 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229920005555 halobutyl Polymers 0.000 description 1
- 125000004968 halobutyl group Chemical group 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910021432 inorganic complex Inorganic materials 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011123 type I (borosilicate glass) Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT23396/82A IT1153974B (it) | 1982-09-23 | 1982-09-23 | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
| IT2339682 | 1982-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8303211A true NL8303211A (nl) | 1984-04-16 |
Family
ID=11206716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8303211A NL8303211A (nl) | 1982-09-23 | 1983-09-16 | Nieuwe farmaceutische preparaten op basis van cisplatinum en werkwijze voor het bereiden daarvan. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4670262A (enExample) |
| JP (1) | JPS5978117A (enExample) |
| AT (1) | AT382077B (enExample) |
| AU (1) | AU559499B2 (enExample) |
| BE (1) | BE897761A (enExample) |
| CA (1) | CA1211372A (enExample) |
| CH (1) | CH655852A5 (enExample) |
| DE (1) | DE3333024A1 (enExample) |
| DK (1) | DK157168C (enExample) |
| FI (1) | FI78236C (enExample) |
| FR (1) | FR2533439B1 (enExample) |
| GB (1) | GB2127291B (enExample) |
| GR (1) | GR79055B (enExample) |
| IE (1) | IE56173B1 (enExample) |
| IL (1) | IL69752A (enExample) |
| IT (1) | IT1153974B (enExample) |
| NL (1) | NL8303211A (enExample) |
| SE (1) | SE464061B (enExample) |
| SU (1) | SU1424722A3 (enExample) |
| ZA (1) | ZA836904B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8303657A (nl) * | 1983-10-24 | 1985-05-17 | Pharmachemie Bv | Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan. |
| IL76889A0 (en) * | 1984-11-02 | 1986-02-28 | Johnson Matthey Plc | Solubilised platinum compound,method for the production thereof and pharmaceutical compositions containing the same |
| JPH0665648B2 (ja) * | 1985-09-25 | 1994-08-24 | 塩野義製薬株式会社 | 白金系抗癌物質の安定な凍結真空乾燥製剤 |
| JP2524217B2 (ja) * | 1988-04-18 | 1996-08-14 | マルハ株式会社 | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤 |
| FI895340A7 (fi) * | 1988-11-14 | 1990-05-15 | Bristol Myers Squibb Co | Hypertoninen cisplatin-liuos |
| US20030148933A1 (en) * | 1990-10-01 | 2003-08-07 | Pharma Mar S.A. | Derivatives of dehydrodidemnin B |
| EP0620004B1 (en) * | 1992-09-04 | 1998-11-25 | Fuji Kagaku Kogyo Kabushiki Kaisha | Medicinal composition |
| FR2759293B1 (fr) * | 1997-02-11 | 1999-04-30 | Ethypharm Lab Prod Ethiques | Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie |
| GB9803448D0 (en) * | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| WO2001035974A2 (en) * | 1999-11-15 | 2001-05-25 | Pharma Mar S.A. | Aplidine treatment of cancers |
| UA76718C2 (uk) * | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| NZ525196A (en) * | 2000-10-12 | 2004-09-24 | Pharma Mar S | Treatment of cancers by aplidine in conjunction with a myoprotector |
| AU2002243646B2 (en) | 2001-01-25 | 2006-06-22 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Formulation of boronic acid compounds |
| RU2178702C1 (ru) * | 2001-02-21 | 2002-01-27 | Общество с ограниченной ответственностью "Нобель" | Антираковое средство |
| CN1283242C (zh) * | 2001-09-21 | 2006-11-08 | 大日本住友制药株式会社 | 冻干制剂 |
| DE60229414D1 (de) * | 2001-10-19 | 2008-11-27 | Pharma Mar Sa | Verwendung von aplidine in der behandlung von pankreaskrebs |
| DK1603584T3 (da) * | 2003-03-12 | 2009-01-05 | Dana Farber Cancer Inst Inc | Aplidine til behandling af multipelt myelom |
| KR20060002778A (ko) * | 2003-03-12 | 2006-01-09 | 파르마 마르, 에스.에이. | 개선된 항종양 치료 |
| ES2278115T3 (es) * | 2003-10-13 | 2007-08-01 | Zoser B. Nat.Rer.Dr. Salama | Composicion farmaceutica que comprende oxoplatino y sus sales. |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| DK2029155T3 (en) * | 2006-02-28 | 2016-08-01 | Pharma Mar Sa | IMPROVED treatment of multiple myeloma |
| CA2703024A1 (en) * | 2007-10-19 | 2009-04-23 | Giuseppe Longo Sorbello | Improved antitumoral treatments |
| MX2010009697A (es) * | 2008-03-07 | 2010-09-30 | Pharm Mar S A | Tratamientos anticancerigenos mejorados. |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| EP2889029A1 (en) | 2008-09-25 | 2015-07-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| CN107773538B (zh) * | 2016-08-27 | 2022-09-13 | 鲁南制药集团股份有限公司 | 稳定的甲啶铂无菌冻干粉末及其制备工艺 |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1432563A (en) * | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
| GB1432562A (en) * | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
| US4053587A (en) * | 1973-04-13 | 1977-10-11 | Research Corporation | Method of treating viral infections |
| US4255417A (en) * | 1976-08-04 | 1981-03-10 | Johnson Matthey, Inc. | Platinum compounds for the irradication of skin blemishes |
| SE445172B (sv) * | 1978-05-30 | 1986-06-09 | Bristol Myers Co | Stabil, steril vattenlosning av cisplatin i enhetsdoseringsform |
| US4273755A (en) * | 1979-08-16 | 1981-06-16 | Mpd Technology Corporation | Preparation of platinum complexes |
| US4302446A (en) * | 1979-10-02 | 1981-11-24 | Bristol-Myers Company | Pharmaceutical compositions |
| US4451447A (en) * | 1980-03-31 | 1984-05-29 | Bristol-Myers Company | Pharmaceutical formulations |
| AU541056B2 (en) * | 1980-03-31 | 1984-12-13 | Bristol-Myers Company | Pharmaceuticals formulations |
-
1982
- 1982-09-23 IT IT23396/82A patent/IT1153974B/it active
-
1983
- 1983-09-12 GB GB08324380A patent/GB2127291B/en not_active Expired
- 1983-09-13 SE SE8304920A patent/SE464061B/sv not_active IP Right Cessation
- 1983-09-13 DE DE3333024A patent/DE3333024A1/de not_active Withdrawn
- 1983-09-13 AU AU19089/83A patent/AU559499B2/en not_active Ceased
- 1983-09-13 AT AT0326283A patent/AT382077B/de active
- 1983-09-14 JP JP58168513A patent/JPS5978117A/ja active Pending
- 1983-09-15 GR GR72452A patent/GR79055B/el unknown
- 1983-09-15 BE BE0/211538A patent/BE897761A/fr not_active IP Right Cessation
- 1983-09-15 FI FI833300A patent/FI78236C/fi not_active IP Right Cessation
- 1983-09-15 CH CH5037/83A patent/CH655852A5/de not_active IP Right Cessation
- 1983-09-15 SU SU833643499A patent/SU1424722A3/ru active
- 1983-09-16 ZA ZA836904A patent/ZA836904B/xx unknown
- 1983-09-16 NL NL8303211A patent/NL8303211A/nl not_active Application Discontinuation
- 1983-09-16 IL IL69752A patent/IL69752A/xx unknown
- 1983-09-16 FR FR8314772A patent/FR2533439B1/fr not_active Expired
- 1983-09-16 DK DK424383A patent/DK157168C/da not_active IP Right Cessation
- 1983-09-16 IE IE2172/83A patent/IE56173B1/en unknown
- 1983-09-20 CA CA000437117A patent/CA1211372A/en not_active Expired
-
1985
- 1985-05-28 US US06/738,436 patent/US4670262A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FR2533439B1 (fr) | 1986-08-14 |
| IL69752A (en) | 1986-07-31 |
| FI78236C (fi) | 1989-07-10 |
| AU1908983A (en) | 1984-03-29 |
| BE897761A (fr) | 1984-01-02 |
| SU1424722A3 (ru) | 1988-09-15 |
| FR2533439A1 (fr) | 1984-03-30 |
| SE8304920D0 (sv) | 1983-09-13 |
| FI833300A7 (fi) | 1984-03-24 |
| FI833300A0 (fi) | 1983-09-15 |
| IE832172L (en) | 1984-03-23 |
| IL69752A0 (en) | 1983-12-30 |
| DK424383D0 (da) | 1983-09-16 |
| DE3333024A1 (de) | 1984-03-29 |
| IE56173B1 (en) | 1991-05-08 |
| CH655852A5 (de) | 1986-05-30 |
| GB2127291B (en) | 1986-01-15 |
| US4670262A (en) | 1987-06-02 |
| AT382077B (de) | 1987-01-12 |
| DK157168B (da) | 1989-11-20 |
| AU559499B2 (en) | 1987-03-12 |
| IT8223396A0 (it) | 1982-09-23 |
| SE8304920L (sv) | 1984-03-24 |
| SE464061B (sv) | 1991-03-04 |
| IT1153974B (it) | 1987-01-21 |
| DK424383A (da) | 1984-03-24 |
| DK157168C (da) | 1990-04-09 |
| GR79055B (enExample) | 1984-10-02 |
| ATA326283A (de) | 1986-06-15 |
| ZA836904B (en) | 1984-10-31 |
| GB8324380D0 (en) | 1983-10-12 |
| JPS5978117A (ja) | 1984-05-04 |
| GB2127291A (en) | 1984-04-11 |
| CA1211372A (en) | 1986-09-16 |
| FI78236B (fi) | 1989-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL8303211A (nl) | Nieuwe farmaceutische preparaten op basis van cisplatinum en werkwijze voor het bereiden daarvan. | |
| CN101172104B (zh) | 抗肿瘤剂,特别是替莫唑胺的药物制剂,其制备方法和用途 | |
| AT402259B (de) | Verfahren zur herstellung eines stabilen pharmazeutischen präparats mit einem gehalt an granulozytkolonie stimulierendem faktor | |
| JPH0313174B2 (enExample) | ||
| RS54973B1 (sr) | Čvrste farmaceutske kompozicije koje uključuju derivate biopterina i upotreba takvih kompozicija | |
| CZ298581B6 (cs) | Farmaceuticky stabilní prípravek oxaliplatiny k parenterální aplikaci | |
| JPH05331071A (ja) | カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法 | |
| HUP0401046A2 (en) | Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan | |
| NL8601698A (nl) | Injecteerbare, voor gebruik gerede oplossingen, die een antracyclineglycoside als antitumormiddel bevatten, werkwijzen voor de bereiding daarvan alsmede een werkwijze voor het remmen van de groei van een tumor. | |
| RU2362557C2 (ru) | Фармацевтическая композиция винфлунина, предназначенная для парентерального введения, способ получения и применение | |
| EP2887953B1 (en) | Improved daptomycin injectable formulation | |
| NL7909199A (nl) | Farmaceutisch preparaat voor het behandelen van nieuw- vormingsziekten en werkwijzen voor het bereiden ervan. | |
| KR860000841B1 (ko) | 시스프라틴의 안정화된 농축용액의 제조방법 | |
| RU97119749A (ru) | Способ лечения рака мочевого пузыря | |
| CN101991857B (zh) | 稳定型药物制剂及其制备方法 | |
| RU2096043C1 (ru) | Антигипоксическое средство и способ его получения | |
| KR101487953B1 (ko) | 유기용매 무함유 젬시타빈 수용액 조성물 | |
| CN1269487C (zh) | 三氧化二砷口服液及其生产方法 | |
| JPS5938207B2 (ja) | 腎疾患治療剤 | |
| CN110237033A (zh) | 一种2,4二硝基苯酚注射液及其制备方法和用途 | |
| Hrubiško et al. | Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump | |
| Sultanova et al. | Chitosan-Based Hydrogel Composition with Megosine | |
| RU2504376C1 (ru) | Высокостабильный фармацевтический состав на основе лиофилизата производных 3-оксипиридинов, или метилпиридинов, или их фармацевтически приемлемых солей | |
| JP2770571B2 (ja) | 安定化された注射剤および注射剤の安定化法 | |
| RU2680804C1 (ru) | Стабильное средство лечения болезней суставов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| CNR | Transfer of rights (patent application after its laying open for public inspection) |
Free format text: ERBAMONT INDUSTRIALE S.R.L. |
|
| DNT | Communications of changes of names of applicants whose applications have been laid open to public inspection |
Free format text: ERBA S.R.L. FARMITALIA CARLO - |
|
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BV | The patent application has lapsed |